Charles Schwab
SPRY icon

Charles Schwab’s ARS Pharmaceuticals SPRY Stock Holding History

Charles Schwab’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.42M Buy
551,416
+18,022
+3% +$155K ﹤0.01% 2535
2026
Q1 		$4.28M Sell
533,394
-17,538
-3% -$168K ﹤0.01% 2468
2025
Q4 		$6.42M Buy
550,932
+30,174
+6% +$293K ﹤0.01% 2336
2025
Q3 		$5.23M Buy
520,758
+78,556
+18% +$1.13M ﹤0.01% 2422
2025
Q2 		$7.72M Buy
442,202
+25,545
+6% +$369K ﹤0.01% 2138
2025
Q1 		$5.24M Sell
416,657
-10,820
-3% -$130K ﹤0.01% 2254
2024
Q4 		$4.51M Buy
427,477
+3,530
+0.8% +$49.4K ﹤0.01% 2373
2024
Q3 		$6.15M Buy
423,947
+8,417
+2% +$100K ﹤0.01% 2269
2024
Q2 		$3.54M Buy
415,530
+70,235
+20% +$623K ﹤0.01% 2511
2024
Q1 		$3.53M Buy
345,295
+15,745
+5% +$117K ﹤0.01% 2416
2023
Q4 		$1.81M Buy
329,550
+5,147
+2% +$22.6K ﹤0.01% 2651
2023
Q3 		$1.23M Buy
324,403
+252,792
+353% +$1.66M ﹤0.01% 2736
2023
Q2 		$480K Buy
71,611
+55,441
+343% +$370K ﹤0.01% 3075
2023
Q1 		$105K Hold
16,170
– – ﹤0.01% 3242
2022
Q4 		$138K Buy
+16,170
New +$105K ﹤0.01% 3230
2022
Q3 		– Sell
-106,414
Closed -$452K – 3547
2022
Q2 		$452K Sell
106,414
-40,961
-28% -$143K ﹤0.01% 3110
2022
Q1 		$518K Sell
147,375
-1,568
-1% -$6.83K ﹤0.01% 3092
2021
Q4 		$992K Buy
148,943
+9,838
+7% +$79.9K ﹤0.01% 2914
2021
Q3 		$1.39M Buy
139,105
+53,301
+62% +$1.31M ﹤0.01% 2774
2021
Q2 		$2.65M Buy
85,804
+1,391
+2% +$44.6K ﹤0.01% 2618
2021
Q1 		$3.68M Buy
+84,413
New +$3.99M ﹤0.01% 2442

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Charles Schwab's SPRY Position: Q2 2026 in Review

Charles Schwab increased its ARS Pharmaceuticals (SPRY) stake by 3.4% in Q2 2026, buying an estimated $155K and bringing the position to 551,416 shares worth $4.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Charles Schwab first reported a position in SPRY in Q1 2021 and has held it in 21 quarters since. The position peaked at $7.72M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Charles Schwab held 551,416 shares of ARS Pharmaceuticals worth $4.42M as of Q2 2026.
  • Charles Schwab bought 18,022 ARS Pharmaceuticals shares in Q2 2026, an estimated $155K.
  • ARS Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2535 holding.
  • Charles Schwab first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Charles Schwab's ARS Pharmaceuticals position peaked at $7.72M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.